Literature DB >> 28143798

Diagnostic histopathology of hepatocellular carcinoma: A case-based review.

Rashmi M Agni1.   

Abstract

Hepatocellular carcinoma (HCC) is the most common primary hepatic malignant neoplasm in adults. Clinically, it tends to present late, and its prognosis historically has been poor, due to limited treatment options at the more advanced stage. A multidisciplinary approach for surveillance and early diagnosis of hepatocellular carcinoma in high-risk populations, combined with advances in surgical and other forms of ablative or chemotherapy, has greatly improved outcomes for patients with this tumor. Liver biopsies for HCC are becoming rare, being performed only for lesions that are atypical on imaging, to avoid the risk of bleeding or of inadvertently seeding the needle tract with HCC. HCC, a tumor of varied appearance, can be diagnostically challenging, particularly on a liver biopsy, due to sampling errors. Although HCC typically occurs on a background of cirrhosis, or advanced fibrosis, it may also arise in the noncirrhotic liver. Well-differentiated HCC may be hard to distinguish from benign lesions in the noncirrhotic liver and premalignant lesions in the cirrhotic liver, whereas a poorly-differentiated neoplasm may be difficult to tell apart from metastases or primary intrahepatic cholangiocarcinoma. Additionally, variant forms of HCC may mimic other neoplasms. This case-based review discusses typical HCC, the increasingly recognized steatohepatitic variant of HCC, the rare scirrhous variant of HCC and the extremely rare and clinically challenging cirrhotomimetic HCC.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Ancillary tests; Cirrhotomimetic; HCC; Hepatocellular carcinoma; Immunohistochemistry; Scirrhous; Steatohepatitic

Mesh:

Year:  2016        PMID: 28143798     DOI: 10.1053/j.semdp.2016.12.008

Source DB:  PubMed          Journal:  Semin Diagn Pathol        ISSN: 0740-2570            Impact factor:   3.464


  5 in total

Review 1.  Hepatocellular nodules in vascular liver diseases.

Authors:  Christine Sempoux; Charles Balabaud; Valérie Paradis; Paulette Bioulac-Sage
Journal:  Virchows Arch       Date:  2018-05-26       Impact factor: 4.064

Review 2.  Morphological, dynamic and functional characteristics of liver pseudolesions and benign lesions.

Authors:  Matteo Renzulli; Nicolò Brandi; Giulia Argalia; Stefano Brocchi; Andrea Farolfi; Stefano Fanti; Rita Golfieri
Journal:  Radiol Med       Date:  2022-01-13       Impact factor: 3.469

3.  MARVELD1 attenuates arsenic trioxide-induced apoptosis in liver cancer cells by inhibiting reactive oxygen species production.

Authors:  Wenping Ma; Haiyang Shen; Qian Li; Hao Song; Yanyan Guo; Fangrong Li; Xingang Zhou; Xinwu Guo; Jingdong Shi; Qi Cui; Jinhao Xing; Jinhai Deng; Youtao Yu; Wenjie Liu; Hongshan Zhao
Journal:  Ann Transl Med       Date:  2019-05

4.  Inositol 1,4,5-trisphosphate receptor type 3 is involved in resistance to apoptosis and maintenance of human hepatocellular carcinoma.

Authors:  Marcone Loiola Dos Santos; Andressa França; Antônio Carlos Melo Lima Filho; Rodrigo M Florentino; Paulo Henrique Diniz; Fernanda Oliveira Lemos; Carlos Alberto Xavier Gonçalves; Vitor Lima Coelho; Cristiano Xavier Lima; Giselle Foureaux; Michael H Nathanson; Paula Vieira Teixeira Vidigal; M Fátima Leite
Journal:  Oncol Lett       Date:  2021-11-25       Impact factor: 2.967

Review 5.  Changing role of histopathology in the diagnosis and management of hepatocellular carcinoma.

Authors:  Archana Rastogi
Journal:  World J Gastroenterol       Date:  2018-09-21       Impact factor: 5.742

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.